Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
News|Articles|May 21, 2025
2025 ACOG Annual Clinical and Scientific Meeting: What you missed
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
Find out what you may have missed at the 2025 ACOG ACSM.
Advertisement
Advertisement
The 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), held in Minneapolis, Minnesota, has officially come and gone, with hundreds of sessions, abstracts, and posters presented on the latest data, recommendations, and calls to action in the women's health care space.
Related to this article
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Advertisement
Advertisement